InMed Pharmaceuticals (INM) Operating Income (2021 - 2025)

InMed Pharmaceuticals' Operating Income history runs 5 years deep, the most recent figure standing at -$2.1 million for Q4 2025.

• On a quarterly basis, Operating Income rose 6.72% year-over-year to -$2.1 million in Q4 2025; TTM through Dec 2025 was -$8.3 million, a 5.49% decrease from a year earlier, with the FY2025 full-year figure at -$7.9 million, up 3.05% from the prior year.
• Operating Income declined to -$2.1 million in Q4 2025 per INM's latest filing, from -$1.8 million in the prior quarter.
• Across five years, Operating Income topped out at -$485150.0 in Q2 2023 and bottomed at -$6.5 million in Q2 2022.
• The 5-year median for Operating Income is -$2.2 million (2023), against an average of -$2.5 million.
• Across the five-year window, Operating Income surged 92.56% in 2023 and slumped 319.3% in 2024, its largest moves.
• Year by year, Operating Income stood at -$4.3 million in 2021, then soared by 48.66% to -$2.2 million in 2022, then rose by 25.7% to -$1.6 million in 2023, then sank by 37.03% to -$2.3 million in 2024, then increased by 6.72% to -$2.1 million in 2025.
• Per Business Quant, the three latest INM Operating Income figures stand at -$2.1 million (Q4 2025), -$1.8 million (Q3 2025), and -$2.5 million (Q2 2025).